227 related articles for article (PubMed ID: 19758641)
21. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
[TBL] [Abstract][Full Text] [Related]
22. Chromophobe renal cell carcinoma with sarcomatoid differentiation: a clinicopathologic study of 14 cases.
Lauer SR; Zhou M; Master VA; Osunkoya AO
Anal Quant Cytopathol Histpathol; 2013 Apr; 35(2):77-84. PubMed ID: 23700716
[TBL] [Abstract][Full Text] [Related]
23. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
Choueiri TK; Xie W; Kollmannsberger C; North S; Knox JJ; Lampard JG; McDermott DF; Rini BI; Heng DY
J Urol; 2011 Jan; 185(1):60-6. PubMed ID: 21074201
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
[TBL] [Abstract][Full Text] [Related]
25. Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy.
Daugherty M; Daugherty E; Jacob J; Shapiro O; Mollapour M; Bratslavsky G
Urol Oncol; 2019 Mar; 37(3):182.e9-182.e15. PubMed ID: 30528396
[TBL] [Abstract][Full Text] [Related]
26. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
[TBL] [Abstract][Full Text] [Related]
27. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database.
Smaldone MC; Handorf E; Kim SP; Thompson RH; Costello BA; Corcoran AT; Wong YN; Uzzo RG; Leibovich BC; Kutikov A; Boorjian SA
J Urol; 2015 Apr; 193(4):1108-13. PubMed ID: 25444991
[TBL] [Abstract][Full Text] [Related]
28. Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis.
Gershman B; Thompson RH; Moreira DM; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
J Urol; 2017 Mar; 197(3 Pt 1):574-579. PubMed ID: 27663461
[TBL] [Abstract][Full Text] [Related]
29. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
30. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
31. The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment.
Bhindi B; Thompson RH; Lohse CM; Mason RJ; Frank I; Costello BA; Potretzke AM; Hartman RP; Potretzke TA; Boorjian SA; Cheville JC; Leibovich BC
Eur Urol; 2018 Oct; 74(4):489-497. PubMed ID: 30017400
[TBL] [Abstract][Full Text] [Related]
32. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
Alhalabi O; Karam JA; Tannir NM
Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
[TBL] [Abstract][Full Text] [Related]
33. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.
de Peralta-Venturina M; Moch H; Amin M; Tamboli P; Hailemariam S; Mihatsch M; Javidan J; Stricker H; Ro JY; Amin MB
Am J Surg Pathol; 2001 Mar; 25(3):275-84. PubMed ID: 11224597
[TBL] [Abstract][Full Text] [Related]
34. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience.
Kader AK; Tamboli P; Luongo T; Matin SF; Bell K; Jonasch E; Swanson DA; Wood CG
J Urol; 2007 Mar; 177(3):855-60; discussion 860-1. PubMed ID: 17296358
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component.
Park I; Cho YM; Lee JL; Ahn JH; Lee DH; Song C; Hong JH; Kim CS; Ahn H
J Cancer Res Clin Oncol; 2013 May; 139(5):817-27. PubMed ID: 23397357
[TBL] [Abstract][Full Text] [Related]
36. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment.
Abel EJ; Culp SH; Matin SF; Tamboli P; Wallace MJ; Jonasch E; Tannir NM; Wood CG
J Urol; 2010 Nov; 184(5):1877-81. PubMed ID: 20850148
[TBL] [Abstract][Full Text] [Related]
37. Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy.
Shuch B; Said J; LaRochelle JC; Zhou Y; Li G; Klatte T; Pouliot F; Kabbinavar FF; Belldegrun AS; Pantuck AJ
Cancer; 2010 Feb; 116(3):616-24. PubMed ID: 19998348
[TBL] [Abstract][Full Text] [Related]
38. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation.
Adibi M; Thomas AZ; Borregales LD; Merrill MM; Slack RS; Chen HC; Sircar K; Murugan P; Tamboli P; Jonasch E; Tannir NM; Matin SF; Wood CG; Karam JA
Urol Oncol; 2015 Oct; 33(10):427.e17-23. PubMed ID: 26004164
[TBL] [Abstract][Full Text] [Related]
39. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.
Culp SH; Karam JA; Wood CG
Urol Oncol; 2014 Jul; 32(5):561-8. PubMed ID: 24709415
[TBL] [Abstract][Full Text] [Related]
40. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma.
Margulis V; McDonald M; Tamboli P; Swanson DA; Wood CG
J Urol; 2009 May; 181(5):2044-51. PubMed ID: 19286220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]